Tag Archives: manager

Anil Chaturvedi Discusses the Reasons European Businesses Should Invest in India

As one of the most experienced and refined bankers in the world, Anil Chaturvedi has come a long way in his career of over forty years and counting. He is currently based in Switzerland, where he is serving as Managing Director of Hinduja Bank, which is one of the most popular private-sector Swiss Banks in Europe. As the Managing Director of the Hinduja Bank, one of the roles of Anil Chaturvedi is to help attract more and more Indians to use the bank to funnel their money back to India, not only for remittances but also for investments. Anil Chaturvedi has also helped the European businesses realize that the trade laws in India has become much more flexible than what it was earlier, and thus, it is the perfect time to invest in India.

Anil Chaturvedi has worked with many banks in his career, which includes ANZ Grindlays Bank, State Bank of India, and Merrill Lynch. At Merrill Lynch, Anil Chaturvedi worked for nearly eighteen years, and he was also the member of the prestigious Circle of Champions. During this time, Barron’s also awarded him the title of one of the Top Financial Advisors in the world. The financial advice provided by Anil Chaturvedi was taken seriously by the financial gurus and investment experts due to his keen sense of equity market and investments. During his stint with State Bank of India, Anil Chaturvedi helped the bank raise over $500 million from new businesses in just four years. The bank awarded him the title of Man of the Year during his tenure with the bank.

Anil Chaturvedi is one of the biggest names in the world of banking and his achievements in the banking industry has made him one of the most sought-after senior banking executives globally. He is associated with Hinduja Bank for nearly six years now during which time, not only has helped in enhancing the revenue of the bank but has also helped promote the bank’s image in the market through various innovative marketing techniques. It has helped the bank to grow consistently as well as sustainably under the leadership of Anil Chaturvedi.

https://fms.almaconnect.com/alumni/company/state-bank-of-india

https://www.epw.in/author/anil-chaturvedi

Sahm Adrangi: The Mastermind Behind Kerrisdale

Whenever there is some misunderstanding in the market, this financial expert Mr. Sahm Adrangi has been on the forefront of dissolving doubts. He is well known for his short selling and publishing various researches on issues that revolve around stocks especially the ones that have hyped very high. The research that Sahm Adrangi does is meant to help investors drop some misconceptions of certain companies and their underlying business prospects. His view is posted on Kerrisdale’s website as well as on twitter. He serves as the Chief Investment Officer in the firm which he founded in 2009 with only $1 million and by July 2017, it had grown to manage $150 million.

Sahm Adrangi was initially heard when he exposed the fraudulent companies in China like China Marine Food Group, Lihua International, and China-Biotics among others. Recently, one of his target areas together with Kerrisdale firm is biotechnology, telecommunications and mining sectors of which he has published researches on several companies. He started his career at Deutsche Bank, Longacre Management, and Chanin Capital Partners. He studied at Yale University for BA in Economics. He has held several conferences as the speaker, appeared in various publications and in several interviews at CNBC.

Sahm Adrangi has published negative news in the Kerrisdale Capital website some of which include their short position in The St. Joe Company (NYSE: JOE) which is a real estate development company that wants to transform desolate land in Panama beach into an attractive site for businesses and the retirees. According to Sahm Adrangi, the investors will continue waiting even longer for any progress to commence.

There has been also a negative report about Proteostasis Therapeutics drug PTI-428 which the financial expert says that the release of the drug is uncertain because it’s encountering issues with the final stage 3 of FDA approval. He also feels that the company is overvaluing itself because it is basing their pricing on low-quality information.

Sahm Adrangi also had a short position on KODAKOne and KODAKCoin which he terms them as flawed and will never offer benefits to its shareholders. Consequently, he said the stock of the company has hyped unjustifiably by 187% just after the partnership was announced. The poor capital structures will still remain even after the ICO craze.

https://endpts.com/kerrisdales-sahm-adrangi-leads-a-brutal-new-biotech-short-attack-as-trial-results-loom/